Adc Therapeutics Ltd Stock News

DUBLIN , March 1, 2022 /PRNewswire/ -- The "Global Cancer Antibody Drug Conjugate Market, Drug Sales, Price, & Clinical Trials Insight 2028" report has been added to ResearchAndMarkets.com''s offering. As per report findings, the global antibody drug conjugate market is expected to surpass US$ 25 billion by 2028, thus registering high CAGR rates. Rising geriatric population associated with high cancer prevalence is one of the major factors which will influence the growth of market. In addition, other factors such as unmet need of targeted cancer therapy, increasing awareness about availability of antibody drug conjugates, rising investments by pharmaceutical companies, development of favorable reimbursement policies, and new product launches will also aid in the growth of market during the forecast period. The report provides comprehensive analysis on the currently available antibody drug conjugates in the market with their commercial information. The report also provides insights into ongoing clinical trials and major antibody drug conjugates in the development, which is expected to enter the market during the forecast period.

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and solid tumors, announced today that Chris Martin, DPhil, Chief Executive Officer, will participate in a fireside chat at Cowen’s virtual 42nd Annual Health Care Conference on Tuesday, March 8th at 2:10 p.m. EST. A live webc

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted an

WASHINGTON, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Vantage Market Research''s recent analysis of the Global Antibody Drug Conjugates (ADCS) Market finds that granted accelerated approval for biologics license applications is expediting market growth. Primarily driven by favourable effective biopharmaceutical medications developed as a targeted therapy for cancer therapy, the total global Antibody Drug Conjugates (ADCS) Market is estimated to reach USD 13.17 Billion by 2028. The Market valued at a revenue of USD 4.24 Billion in 2021, and is expected to grow at a Compound Annual Growth Rate (CAGR) of 18.9%. Furthermore, the rising benefit of Antibody Drug Conjugates (ADCS) as the unharmed healthy cells enable patients to recover quickly, thus growth of the Global Antibody Drug Conjugates (ADCS) Market, states Vantage Market Research, in a report, titled " Antibody Drug Conjugates (ADCS) Market by Application (Breast Cancer, Urothelial Cancer & Bladder Cancer, Other Cancer, Blood Cancer), by Technology (Cleavable Linker, Non-Cleavable Linker, Linkerless), by Region (North America, Europe, Asia Pacific, Latin America) - Global Industry Assessment (2016 - 2021) & Forecast (2022 - 2028)".

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted an

ADC Therapeutics (ADCT) has signed an exclusive license agreement with Mitsubishi Tanabe Pharma Corporation ((MTPC)) for the development and commercialization of ZYNLONTA

ADC Therapeutics SA (NYSE: ADCT) has entered an exclusive license agreement with Mitsubishi Tanabe Pharma Corporation to develop and commercialize Zynlonta (loncastuximab tesirine-lpyl) for all h

The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative development. The sector r

Morgan Stanley increased its stake in ADC Therapeutics SA (NYSE:ADCT) by 22.2% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 249,527 shares of the companys stock after purchasing an additional 45,300 shares during the quarter. Morgan Stanley owned approximately 0.36% of ADC []

ADC Therapeutics SA (NYSE:ADCT) has been given a consensus recommendation of Buy by the seven brokerages that are presently covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12-month target price among brokerages that have issued []

Shares of ADC Therapeutics SA (NYSE:ADCT) dropped 6% during trading on Friday . The company traded as low as $26.21 and last traded at $26.21. Approximately 2,188 shares changed hands during mid-day trading, a decline of 99% from the average daily volume of 278,913 shares. The stock had previously closed at $27.88. ADCT has been []

ADC Therapeutics SA (ADCT) CEO Christopher Martin on Q3 2021 Results - Earnings Call Transcript

ADC Therapeutics SA (ADCT) delivered earnings and revenue surprises of 39.18% and 69.86%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock

ADC Therapeutics (ADCT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.